BIGBLOC Const. (BIGBLOC)
CyclicalFairStock Score: 16/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹44.95 |
| Market Cap | ₹636.38 Cr |
| P/E Ratio | 0 |
| ROCE | 6.63% |
| ROE | -12.83% |
| Dividend Yield | 0% |
| Profit Growth | -15.14% |
| Debt/Equity | 1.38 |
| Sales Growth | 40.4% |
| Promoter Holding | 72.81% |
| 52-Week Range | ₹38 — ₹80 |
| Sector | Cement & Cement Products |
| Book Value | ₹9.72 |
Strengths
- Sales growth of 28.14% shows decent demand traction in cement products.
- Promoter holding of 72.81% ensures significant skin in the game.
- Positive ROCE of 6.63% shows the asset base is generating some operating return.
- Latest quarter sales of ₹73 Cr show meaningful operating scale, even if profits are zero.
Concerns
- Latest quarter net profit is ₹0 Cr and full-year profit growth is -15.14%, leaving no earnings support for the valuation.
- P/B of 11.82 against book value of ₹4.04 is extreme; investors pay ₹47.76 for each ₹4.04 of equity while ROE is negative.
- Debt/equity of 1.40 is high; with negative ROE, leverage magnifies financial risk.
- Piotroski F-Score of 4/9 and FairStock Score of 14/100 indicate poor financial health, and there is no dividend.
AI Analysis
Let me begin with a simple test: can this company earn a decent return on capital? At BIGBLOC, the numbers say no. The latest quarter had sales of ₹73 Cr but net profit of ₹0 Cr. Full-year profit growth is -15.14%, and return on equity is -12.83%. A business that earns nothing on shareholders' equity does not deserve my money. I also look at price versus what I get in tangible value. The book value is ₹4.04 per share, yet the market is asking ₹47.76. That's roughly 11.8 times book. For a company with negative ROE and debt-to-equity of 1.40, this is no margin of safety. Graham would have balked at paying almost twelve times book for an unprofitable, leveraged cement player. Sales did grow 28.14%, and the cement products industry can benefit from infrastructure spending. But top-line growth without bottom-line profit is like a diet where you eat more and weigh more. ROCE is only 6.63%, which is likely below the cost of capital, and the Piotroski score of 4/9 suggests poor financial health. There is no dividend yield; the only possible return is speculative price appreciation. The 52-week range of ₹38 to ₹80 shows how volatile this stock is. At ₹47.76, it is below the midpoint, but "down from high" is not a reason to buy. Promoter holding at 72.81% is a positive, but even aligned owners cannot substitute for weak economics. I would wait for evidence of debt reduction, positive net earnings, and a return on equity that exceeds the cost of capital. Until then, this is a cyclical risk, not an investment.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer